Regulation, clinical context, and evidence-based harm reduction Cigarette smoking continues to impose a disproportionate health burden in Appalachia, a region marked by persistently high smoking prevalence, elevated rates of cardiovascular
A Deep Dive into the Future of Novel NicotineWe wish to share the latest episode of the Tobacco Asia / InterTabac podcast, where GINN’s Director Shem Baldeosingh joins Thomas Schmid
Recent analysis published in The Lancet Public Health reinforces a long-standing but often overlooked reality in tobacco control: nicotine use is not a monolith, and public-health outcomes depend critically on
Nicotine pouch performance is often discussed almost exclusively in terms of formulation. Nicotine concentration, pH, buffering systems, flavour chemistry, and moisture balance dominate both technical development and regulatory review. These
🇨🇳 China Confirms Nicotine Pouches Are Now Under the State Tobacco Monopoly China’s move to classify nicotine pouches within the state tobacco monopoly is now confirmed not only by specialist
Youth “addiction” to nicotine pouches and other smoke-free nicotine products is increasingly invoked as a political shorthand, often without reference to how addiction is actually defined in modern clinical science.
Expectations around the European Union’s next revision of the Tobacco Products Directive (TPD3) have continued to shift, but a clearer picture is now emerging. Based on Commission planning documents, specialised
As nicotine pouches gain visibility in the United States and other markets, debate around their public-health role has intensified. Much of this discussion has been driven by concern over youth
As nicotine pouch use expands globally, regulatory debate is increasingly framed as a choice between bans and permissive access. That framing is misleading. Evidence now points toward a more effective
Why excise policy matters for harm reduction in Europe Europe’s nicotine policy framework is entering a critical phase. Recent reporting on draft revisions to the EU Tobacco Excise Directive suggests
Recent media coverage of a report examining nicotine’s effects on the heart and blood vessels has renewed debate about cardiovascular risk and nicotine regulation. In response, experts contributing to the
As nicotine markets continue to evolve, regulators are increasingly challenged to design policies that protect young people while also reflecting the growing body of evidence on relative risk among nicotine